Januvia And Onglyza In, Galvus Out, As Germany Evaluates Older Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s G-BA has panned Novartis’ Galvus, but retained Merck’s Januvia and Bristol/AstraZeneca’s Onglyza as it starts culling older drugs.
You may also be interested in...
Germany's G-BA Sets Out Financial-Based Criteria For Assessing Drugs Already On The Market
Germany's senior reimbursement body, the G-BA, has set out criteria – based on the financial success of products – to evaluate drugs already on the market.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.